GenomOncology Pathology Workbench to support OmniSeq INSIGHT℠, a genomic and immune profiling test that identifies potential treatment and clinical trial options for solid tumors

CLEVELAND, Jan. 12, 2022 — GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp's OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test for solid tumors.

Labcorp strengthens oncology leadership position with the addition of Personal Genome Diagnostics, a provider of comprehensive liquid biopsy and tissue-based genomic products and services

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 23, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.

Labcorp and ConcertAI optimize precision oncology research with real-world data and artificial intelligence

BURLINGTON, N.C. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 1, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, and ConcertAI, LLC (ConcertAI), a leader in enterprise artificial intelligence (AI) and real-world data (RWD) solutions for life science companies and health care providers, today announced a collaboration to optimize precision oncology research. The companies will work together to launch clinical studies in ways that minimize the burden on physician practices, drive faster patient recruitment, maximize patient retention and ensure equitable access to research as a care option.